Design Therapeutics, Inc. Revenue
Design Therapeutics, Inc. (DSGN) reported Revenue of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-03
- Design Therapeutics, Inc. revenues for the quarter ending 2026-06-30 was $0.00.
- Design Therapeutics, Inc. revenues for the quarter ending 2026-03-31 was $0.00.
- Design Therapeutics, Inc. revenues for the quarter ending 2025-12-31 was $0.00.
- Design Therapeutics, Inc. revenues for the quarter ending 2025-09-30 was $0.00.
- Design Therapeutics, Inc. revenues for fiscal 2025 was $0.00.
- Design Therapeutics, Inc. revenues for fiscal 2024 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-28 | $0.00 derived: sum of 2 quarters · filed 2026-04-28 | $0.00 derived: sum of 3 quarters · filed 2026-04-28 | $0.00 derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |